Immunoinformatics mapping of potential epitopes in SARS-CoV-2 structural proteins.

Immunoinformatics mapping of potential epitopes in SARS-CoV-2 structural proteins.

Mostrar otras versiones (1)

All approved coronavirus disease 2019 (COVID-19) vaccines in current use are safe, effective, and reduce the risk of severe illness. Although data on the immunological presentation of patients with COVID-19 is limited, increasing experimental evidence supports the significant contribution of B and T...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yengkhom Damayanti Devi, Himanshu Ballav Goswami, Sushmita Konwar, Chandrima Doley, Anutee Dolley, Arpita Devi, Chen Chongtham, Dikshita Dowerah, Vashkar Biswa, Latonglila Jamir, Aditya Kumar, Siddhartha Shankar Satapathy, Suvendra Kumar Ray, Ramesh Chandra Deka, Robin Doley, Manabendra Mandal, Sandeep Das, Chongtham Shyamsunder Singh, Partha Pratim Borah, Pabitra Nath, Nima D Namsa
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/3141d809c7674c04ad839292d586c3f9
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:All approved coronavirus disease 2019 (COVID-19) vaccines in current use are safe, effective, and reduce the risk of severe illness. Although data on the immunological presentation of patients with COVID-19 is limited, increasing experimental evidence supports the significant contribution of B and T cells towards the resolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Despite the availability of several COVID-19 vaccines with high efficacy, more effective vaccines are still needed to protect against the new variants of SARS-CoV-2. Employing a comprehensive immunoinformatic prediction algorithm and leveraging the genetic closeness with SARS-CoV, we have predicted potential immune epitopes in the structural proteins of SARS-CoV-2. The S and N proteins of SARS-CoV-2 and SARS-CoVs are main targets of antibody detection and have motivated us to design four multi-epitope vaccines which were based on our predicted B- and T-cell epitopes of SARS-CoV-2 structural proteins. The cardinal epitopes selected for the vaccine constructs are predicted to possess antigenic, non-allergenic, and cytokine-inducing properties. Additionally, some of the predicted epitopes have been experimentally validated in published papers. Furthermore, we used the C-ImmSim server to predict effective immune responses induced by the epitope-based vaccines. Taken together, the immune epitopes predicted in this study provide a platform for future experimental validations which may facilitate the development of effective vaccine candidates and epitope-based serological diagnostic assays.

Ejemplares similares